On the other hand, HFE diminished lipid metabolism targets implicated in de novo lipogenesis and cholesterogenesis (including SREBF1, FASN, SCD, SREBF2, and HMGCR), and two metabolic axes—ABCA1 [4] and ACSL1/ACSL4/SCD network [3]—were described to promote invasion and migration and to correlate with poorer prognosis in CRC patients. The gene discussed is FASN; the disease is colorectal carcinoma.